Manufacturing Supplement Reviews Will Not Lag Under PDUFA, FDA Says
Executive Summary
Manufacturing supplement resubmissions will not suffer from a lack of review goals under PDUFA, Center for Biologics Evaluation & Research Associate Director for Review Management Robert Yetter, PhD, maintained during the Biotechnology Industry Organization annual meeting June 12
You may also be interested in...
Aventis To Increase Fluzone Supply As Wyeth’s FluShield Exits Market
Aventis-Pasteur is in discussions with FDA and the Centers for Disease Control & Prevention on ways to increase the supply of its influenza vaccine Fluzone following Wyeth's decision to discontinue FluShield
Aventis To Increase Fluzone Supply As Wyeth’s FluShield Exits Market
Aventis-Pasteur is in discussions with FDA and the Centers for Disease Control & Prevention on ways to increase the supply of its influenza vaccine Fluzone following Wyeth's decision to discontinue FluShield
Wyeth Will Lose 18.5% Of Marietta Sales If Firm Does Not Comply With GMPs
Wyeth-Ayerst would have to pay the government 18.5% of future net sales from products manufactured at its Marietta, Penn. facility if it fails to meet a timeline for bringing the plant into compliance with current Good Manufacturing Practices under an Oct. 3 consent decree with FDA.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: